266 related articles for article (PubMed ID: 33791360)
1. The Predictive Efficacy of Tumor Mutation Burden (TMB) on Nonsmall Cell Lung Cancer Treated by Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Nan Z; Guoqing W; Xiaoxu Y; Yin M; Xin H; Xue L; Rong W
Biomed Res Int; 2021; 2021():1780860. PubMed ID: 33791360
[TBL] [Abstract][Full Text] [Related]
2. Predictive Efficacy of Blood-Based Tumor Mutation Burden Assay for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Zhang N; Zhang J; Wang G; He X; Mi Y; Cao Y; Yu X
Front Oncol; 2022; 12():795933. PubMed ID: 35223476
[TBL] [Abstract][Full Text] [Related]
3. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Ba H; Liu L; Peng Q; Chen J; Zhu YD
BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
[TBL] [Abstract][Full Text] [Related]
4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
5. Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients.
Chen X; Fang L; Zhu Y; Bao Z; Wang Q; Liu R; Sun W; Du H; Lin J; Yu B; Chen S; Zhou J; Zhou J
Cancer Immunol Immunother; 2021 Dec; 70(12):3513-3524. PubMed ID: 33899131
[TBL] [Abstract][Full Text] [Related]
6. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
7. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
8. Tumor mutational burden as a predictive biomarker for non-small cell lung cancer treated with immune checkpoint inhibitors of PD-1/PD-L1.
Shao MM; Xu YP; Zhang JJ; Mao M; Wang MC
Clin Transl Oncol; 2024 Jun; 26(6):1446-1458. PubMed ID: 38190035
[TBL] [Abstract][Full Text] [Related]
9. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
[TBL] [Abstract][Full Text] [Related]
10. The association of efficacy with PD-1/PD-L1 inhibition and tumor mutational burden in advanced nonsmall cell lung cancer: A PRISMA-guided literature review and meta-analysis.
Yu D; Yuan C; Zhang H; Chu W
Medicine (Baltimore); 2022 Jul; 101(29):e29676. PubMed ID: 35866790
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of tumor mutational burden for immunotherapy in non-small cell lung cancer: A systematic review and meta-analysis.
Meng G; Liu X; Ma T; Lv D; Sun G
PLoS One; 2022; 17(2):e0263629. PubMed ID: 35113949
[TBL] [Abstract][Full Text] [Related]
12. How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Chen H; Han KD; He ZJ; Huang YS
Technol Cancer Res Treat; 2021; 20():15330338211033498. PubMed ID: 34323149
[TBL] [Abstract][Full Text] [Related]
13. Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer.
Frigola J; Navarro A; Carbonell C; Callejo A; Iranzo P; Cedrés S; Martinez-Marti A; Pardo N; Saoudi-Gonzalez N; Martinez D; Jimenez J; Sansano I; Mancuso FM; Nuciforo P; Montuenga LM; Sánchez-Cespedes M; Prat A; Vivancos A; Felip E; Amat R
Mol Oncol; 2021 Apr; 15(4):887-900. PubMed ID: 33342055
[TBL] [Abstract][Full Text] [Related]
14. Prediction performance comparison of biomarkers for response to immune checkpoint inhibitors in advanced non-small cell lung cancer.
Zhao J; Zhuang W; Sun B; Bai H; Wang Z; Zhong J; Wan R; Liu L; Duan J; Wang J
Thorac Cancer; 2024 May; 15(13):1050-1059. PubMed ID: 38528429
[TBL] [Abstract][Full Text] [Related]
15. Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Li Y; Ma Y; Wu Z; Zeng F; Song B; Zhang Y; Li J; Lui S; Wu M
Front Immunol; 2021; 12():751407. PubMed ID: 34659255
[TBL] [Abstract][Full Text] [Related]
16. The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
Hu X; Xu H; Xue Q; Wen R; Jiao W; Tian K
Mol Med; 2021 Oct; 27(1):126. PubMed ID: 34620079
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
Wang Z; Duan J; Cai S; Han M; Dong H; Zhao J; Zhu B; Wang S; Zhuo M; Sun J; Wang Q; Bai H; Han J; Tian Y; Lu J; Xu T; Zhao X; Wang G; Cao X; Li F; Wang D; Chen Y; Bai Y; Zhao J; Zhao Z; Zhang Y; Xiong L; He J; Gao S; Wang J
JAMA Oncol; 2019 May; 5(5):696-702. PubMed ID: 30816954
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC.
Ishii H; Azuma K; Kawahara A; Kinoshita T; Matsuo N; Naito Y; Tokito T; Yamada K; Akiba J; Hoshino T
Thorac Cancer; 2020 Apr; 11(4):950-955. PubMed ID: 32061060
[TBL] [Abstract][Full Text] [Related]
19. The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials.
Galvano A; Gristina V; Malapelle U; Pisapia P; Pepe F; Barraco N; Castiglia M; Perez A; Rolfo C; Troncone G; Russo A; Bazan V
ESMO Open; 2021 Jun; 6(3):100124. PubMed ID: 33940346
[TBL] [Abstract][Full Text] [Related]
20. Predictors of Survival Benefit From Immune Checkpoint Inhibitors in Patients With Advanced Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis.
Raphael J; Batra A; Boldt G; Shah PS; Blanchette P; Rodrigues G; Vincent MD
Clin Lung Cancer; 2020 Mar; 21(2):106-113.e5. PubMed ID: 31992521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]